ArticleHereditas2025
Regulatory effect of miR-142-5p on inflammatory process of sepsis by targeting CXCL8.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Salivary MicroRNA Reflects Neurodevelopment and Oral Health Traits in Children With Autism.International dental journal · 2026Observational
- Downregulated miR-1290 serves as a diagnostic and prognostic biomarker in sepsis and protects against inflammatory injury by targeting TAOK1.BMC immunology · 2026Article
- Systematic characterization of pyroptosis-related gene patterns identifies potential prognostic inflammatory phenotypes in sepsis.Functional & integrative genomics · 2026Article
- Serum LINC01127 serves as a diagnostic biomarker for sepsis and its predictive value for clinical outcomes.Hereditas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is a life-threatening systemic inflammatory response triggered by infection. The rapid progression of the disease necessitates early diagnosis and precise intervention, making the identification of reliable biomarkers and therapeutic targets crucial for improving clinical outcomes and reducing sepsis-related mortality.
aimExploring miR-142-5p as a novel diagnostic biomarker for sepsis and its therapeutic potential via targeting CXCL8.
methodsThe expression levels of inflammatory factors (IL-6, TNF-α, IL-1β) and miR-142-5p in the serum of patients with sepsis and healthy controls were detected by ELISA and qPCR methods respectively. The diagnostic potential of miR-142-5p was evaluated using Pearson correlation, ROC curve, and logistic regression analyses. Bioinformatic prediction and dual-luciferase assays identified CXCL8 as a target, while LPS-induced models and cell transfection experiments investigated miR-142-5p's therapeutic effects through CXCL8 regulation.
resultsSepsis patients exhibited significantly decreased miR-142-5p expression, inversely correlating with inflammatory markers (IL-6, TNF-α, IL-1β). ROC analysis showed excellent diagnostic value (AUC = 0.917). Pearson correlations indicated significant clinical associations, while logistic regression identified miR-142-5p as an independent protective factor (HR = 0.498, 95% CI:0.282-0.882, P = 0.017). LPS models confirmed miR-142-5p's anti-inflammatory effects through cytokine suppression, with knockdown showing opposite effects. Mechanistically, dual-luciferase and transfection assays verified CXCL8 as a direct target mediating these effects.
conclusionmiR-142-5p may alleviate sepsis by targeting CXCL8-mediated inflammation, suggesting its potential as a diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.